Currently, dose-escalation in the OTS167 clinical trial is proceeding to determine a maximum tolerated dose and biologically effective dose that could be tested in combination therapy using OTS167 with gilteritinib in FLT3 mutant AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.